UCM-1306

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

UCM-1306 是一种口服有效的人多巴胺 D1 受体变构调节剂 (PAM)。UCM-1306 增加人和小鼠 D1 受体中的内源性多巴胺 (DA) 最大效应。UCM-1306 不仅可以改善运动症状，还可以解决与长期帕金森病 (PD) 相关的关键共病认知障碍。

UCM-1306 is a potent and orally active human dopamine D1 receptor allosteric modulator (PAM). UCM-1306 increases the endogenous dopamine (DA) maximal effect both in human and mouse D1 receptors. UCM-1306 is not only for improving motor symptoms but also for addressing the key comorbid cognitive impairment associated with long-term Parkinson’s disease (PD).

——

Animal Model:Adult C57BL/6J mice with cocaine-induced hyperactivity model Dosage:1 mg/kg; cocaine (20 mg/kg, sc) Administration:Intraperitoneal injection Result:Increased cocaine-induced hyperlocomotion, suggesting an in vivo potentiation of DA action at the D1R.Animal Model:Adult C57BL/6J mice Dosage:1 mg/kg Administration:Intraperitoneal injection Result:Increased memory trace in C57BL/6J mice.

——

GPCR/G Protein

Dopamine Receptor

Dopamine Receptor

——

——

2258608-78-3

279.33

C14H14FNO2S

>98% (HPLC)

In Vitro:?DMSO 中的溶解度 : 50 mg/mL (179.00 mM; 超声助溶 )

CS(=N)(=O)c1ccc(cc1)-c1ccccc1OCF

——

(-20℃)

With Ice Pack

≥ 2 years